TIMETABLE
REGISTRATION
ABSTRACTS
HOTELS
BTOG 2027 will be held at the EICC Edinburgh from Wednesday 3rd to Friday 5th March 2027.
BTOG 2027 is sponsored by multiple sponsors from the pharmaceutical, medical, and legal industry. Sponsors have solely provided financial sponsorship, and sponsors have not been involved or influenced the content or agenda.
To learn more about our 2026 Annual Conference, visit the Archive page where you can download the programme, read session summaries, see photos and watch videos.
Timetable
Registration
Online Registration is now open
Registration Rates
| Registration Rate | BTOG 2027 - 3 days |
|---|---|
| Concessionary rate for All Nurses, AHPs, Screening and Clinical Trial Personnel and All Drs before CCT completion including Medical Students | £330 |
| Full rate for Drs with CCT - Consultants, Academic Professors and other senior personnel | £600 |
| Per day charge for concessionary and full rate | £220 per day |
| Conference Dinner (all) | £85 |
| Non-profit and patient group rate | £330 |
| Sponsor industry rate *outside sponsor level | £770 +VAT £275 +VAT per day |
| Agency/satellite meeting day pass – max 2 | £FOC day of satellite only (otherwise £275 +VAT per day) |
| Non-sponsors industry rate | £360 +VAT per day |
As an eligible body for VAT purposes the supply of education at BTOG educational events is exempt from VAT for healthcare professionals.
Registration Cancellation Policy
For cancellations received 28 days or more before the first day of the annual conference, we will refund registration fees paid, minus a £25 administration charge. If registration has not been paid, then a £25 administration charge will still be payable. No refunds are payable for cancellations received within 27 days of the first day of the annual conference and if registration has not been paid the full registration fee will still be payable. This will include cancellations or non-attendance due to travel difficulties or other matters that are out of BTOG’s control.
Hotels
| Logo | Description | Distance | Rates | How to Book |
|---|---|---|---|---|
| Leonardo Hotel Edinburgh Haymarket | ||||
|
Leonardo offers three well-located hotels in Edinburgh, each with its own character. Leonardo Hotel Edinburgh Haymarket is the designated conference hotel and is a modern 4-star property just minutes from Haymarket station, featuring stylish rooms, an on-site bar and grill, and excellent access to city highlights. | 6 minute walk from the conference venue | £120.00 Single / £135.00 Double |
Visit
www.leonardohotels.co.uk
Enter LHVENV010327 in the Promo code box along with dates and select Leonardo Haymarket hotel. |
| Hampton by Hilton Edinburgh West End | ||||
|
Hampton by Hilton Edinburgh West End is a modern hotel located just a short walk from the city’s main attractions. It features contemporary rooms with free WiFi, access to a fitness centre and on-site bar and restaurant. | 9 minute walk from the conference venue | £123.00 Single / £133.00 Double |
Accommodation can be booked directly via this link: https://group.hamptoninn.com/f0wli8 |
| Four Points by Sheraton Edinburgh | ||||
|
Four Points by Sheraton Edinburgh is a stylish 4-star hotel conveniently located in Edinburgh’s West End, just steps from Haymarket train and tram connections. | 15 minute walk from the conference venue | £105.00 Single / £115.00 Double |
Guests can email our in-house reservations team quoting BTOG 2027
to book their own accommodation. E: reservations@fourpointsedinburgh.com |
Abstracts
BTOG 2027 Abstract Submission is now open
Please note you will need to register as a new user even if you have submitted an abstract last year and the abstract submission is not linked to your BTOG membership login.
- Abstract submission closes: Monday 7th December 2026 23:59 GMT
- Abstract notification: Monday 11th January 2027
- Call for abstract submissions for original, previously unpublished, research or audit related to thoracic malignancy, as a poster abstract.
- Encore abstracts: BTOG’s position on encore abstracts is that an abstract/poster submitted/presented at another conference and then submitted to BTOG 2027 must contain additional information or data to the original and the previous submission/presentation must be declared on the submission.
- The abstract maximum is 300 words and any references also form part of the total word count. The abstract title is not included in the word count and in addition you can include one diagram or table. Please note the published abstracts will be in black and white print only and therefore please ensure the diagram or table is clear and readable in black and white print.
- Case reports can be submitted for consideration, these are generally only accepted if there is a significant learning point associated with the case or series of cases.
- All submitted abstracts will be considered for an oral presentation at BTOG 2027. By submitting an abstract, BTOG requests that one of the authors commit to delivering an oral presentation in the Annual Conference if selected.
Abstract/Poster Notifications sent by email on 11th January 2027 for the following:
Abstract Submission – Acceptance – Poster sent by btog@venuesworld.com
Abstract Submission – Oral Presentation sent by dawn.mckinley@btog.org
Abstract Submission – Rejection sent by dawn.mckinley@btog.org
If email not received please check spam/junk email and if not received email as above with original submission ID and abstract title.
By submitting an abstract, one of the authors confirmed they will register and attend BTOG 2027, and registration rates apply.
BTOG 2027 Abstracts will be published in a Supplement to the journal Lung Cancer – this will be published and released at BTOG 2027. Published abstracts will be printed in black and white only.
Posters
BTOG 2027 Posters
- Posters will be presented in-person at BTOG 2027 and displayed on physical boards.
- The poster submitter is responsible for the cost and arranging the printing of the poster and bringing or transporting to BTOG 2027.
- BTOG will provide a link to a paid option for printing and shipping of fabric posters and information will be added as soon as available.
- Posters will need to be up and available for viewing by latest 12:00 noon on Wednesday 3rd March 2027 until 18:00 on Thursday 4th March.
- There will be a formal poster viewing and welcome reception at 18:30 – 20:00 on Wednesday.
Want to know what happened at BTOG26?
Check out our summary page and then you can login or join BTOG to see the session recordings and presentations.
See some of the highlights in our slideshow.
11.00-12.30
Part 1
BTOG Therapeutics Symposium
Immune Cell Engagers
Chairs: Shobhit Baijal (ENG) and Yvonne Summers (ENG)
Gary Middleton (ENG)
Sarah Blagden (ENG)
Fiona Thistlethwaite (ENG)
Jane Robertson (ENG)
14.00-15.00
Part 2
BTOG Therapeutics Symposium
SACT in CNS Disease
Chairs: Samreen Ahmed (ENG) and Paolo d’Arienzo (ENG)
Lizza Hendriks (NLD)
Natasha Leighl (CAN)
Antonio Calles (ESP)
11.00-12.30
Part 1
BTOG Radiotherapy Symposium
Pushing the Boundaries in Lung Cancer
Chairs: Ceri Powell (WAL) and Gerard Walls (IRL)
Crispin Hiley (ENG)
Sohaib Nazir (ENG)
Corinne Faivre-Finn (ENG)
Tanya Ahmad (ENG)
Pandora Rudd (ENG)
14.00-15.00
Part 2
BTOG Radiotherapy Symposium
BTOG Complex Cases MDT
Chairs: Clive Peedell (ENG) and Kishen Patel (ENG) Expert Panel: Maggie Harris (ENG), Andrea Filippi (ITA), Riyaz Shah (ENG), Gerry Hanna (IRL) and Iain Phillips (SCT)
Oghenevwede Okuma (ENG)
Heba Abdelaal (ENG)
Lara Philipps (ENG)
Darragh Browne (IRL)
11.00-12.30
Part 1
BTOG Diagnostics Symposium
Diagnostic Challenges
Chairs: Daniel Steinfort (AUS) and Sinan Eccles (WAL)
Anna Bibby (ENG)
Annette Johnstone (ENG)
Matthew Evison (ENG)
Raphael Werner (CHE)
14.00-15.00
Part 2
BTOG Diagnostics Symposium
Mesothelioma
Chairs: Avinash Aujayeb (ENG) and Liz Darlison (ENG)
Selina Tsim (SCO)
Phil Reid (SCO)
Eleanor Mishra (ENG)
BTOG defines advocates, as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.
Topic 1: Role of pathology in lung cancer
Discussion
Topic 2: Quality of life considerations
Discussion
Facilitator: Cecilia Pompili
16.30-17.30
Chair: Tom Newsom-Davis (ENG)
Tom Newsom-Davis
Neal Navani (ENG)
Nick Maskell (ENG)
Robert Rintoul (ENG)
Heather Wakelee (USA)
| 09:00 – 10:30 | Session 4: Lung Cancer Research: Make the UK Great Again |
LEVEL 3 PENTLAND Chairs: Samantha Cox (WAL) and David Meek (ENG) |
| 09:00 | UK Research Infrastructure 2026 | Philippa Corrie (ENG) |
| 09:15 | Improving and Excelling Academic Research | Sarah Halford (ENG) |
| 09:30 | Learning from Experience: How to succeed and fail in clinical trials | Eric Lim (ENG) |
| 09:45 | Global Research: Can the UK Compete? | Gregory Lubiniecki (ENG) |
| 10:00 | Panel Discussion | |
| 10:30 | Close |
| 12:15 – 13:00 | Session 6: BTOG/Association of Pulmonary Pathologists (APP) Joint Plenary: New Approaches in Stage III NSCLC |
LEVEL 3 PENTLAND Chairs: David Snead (ENG) and Fiona McDonald (ENG) |
| 12:15 | Evaluating Pathological Response After Neo-Adjuvant Therapy | TBC |
| 12:30 | How Should we Manage Borderline Resectable NSCLC? | Andrea Filippi (ITA) |
| 12:45 | NSCLC in Patients Unsuitable for Concurrent Chemoradiotherapy | Gerry Hanna (IRE) |
| 13:00 | Close |
| 14:15 – 15:45 | Session 7: BTOG/Society for Cardiothoracic Surgery in Great Britain & Ireland (SCTS) Joint Plenary |
LEVEL 3 SIDLAW/PENTLAND Chairs: Cecilia Pompili (ENG) and Alan Kirk (SCO) |
| 14:15 | Resectability and Operability: Pushing the Boundaries | Annabel Sharkey (ENG) |
| 14:35 | Chest & Lung Surgery Priority Setting Partnership: James Lind Alliance Results | Babu Naidu (ENG) |
| 14:55 | Thoracic Surgery in 10 Years’ Time: Role In The Management of Thoracic Malignancies | Aman Coonar (ENG) |
| 15:15 | Panel Discussion | |
| 15.45 | Close |
| 14:00 – 15:45 |
Association Pulmonary Pathologists (APP) Session Open to non-APP members |
LEVEL -1 MENTEITH Chair: David Snead (ENG) |
| 14:00 | Sub-lobar surgical resection of pulmonary carcinoma – who and how | Sabrina Siregar (NL) |
| 14:30 | Spread through adjacent airspaces diagnosis and relevance | Jan von der Thüsen (NL) |
| 15:00 | Panel discussion how to handle close margins | Sabrina Siregar (NL), Jan von der Thüsen (NL), Andrew Robinson (ENG), and Alexander Harragan (ENG) |
| 15:15 | Case 1 Discussion | |
| 15:30 | Case 2 Discussion | |
| 15.45 | Close |
| 17:00 – 18:00 |
Session 8: Poster Oral Presentations, Poster Prizes and BTOG 2026 Awards 5 minutes presentation + 5 minutes discussion each |
LEVEL 3 SIDLAW/PENTLAND Chair: Matthew Evison (ENG) and Paula Shepherd (ENG) |
| 17:00 | Introduction | |
| 17:05 | Lung Cancer Screening Prison Pilot – HMP Holme House | Liz Fuller (ENG) |
| 17:15 | Enhanced Detection Rate of AI for Lung Cancer Detection on GP-Referred Chest X-rays | Anubhav Datta (ENG) |
| 17:25 | Lung cancer in never smokers (LCINS): Clinicopathological characteristics of patients treated at Guy’s cancer centre, South-East London Cancer Alliance | Alexandra Holdich (ENG) |
| 17:35 | Identifying incidence of malnutrition in lung cancer patients attending Northern Centre for Cancer Care (NCCC) outpatient clinic | Lillian Marcantonio (ENG) |
| 17:45 | Poster Prizes and BTOG 2026 Award Announcements • BTOG 2026 Nurse of the Year Award • BTOG 2026 Doctor of the Year Award • BTOG 2026 Young Researcher of the Year Award |
Matthew Evison (ENG) Tom Newsom-Davis (ENG) |
| 18.00 | Close |
| 09:00 – 10:30 |
Session 9: State of the Union: EBUS in the UK 2026 |
LEVEL 3 SIDLAW/PENTLAND Chairs: Neal Navani (ENG) and Tanya Patrick (ENG) |
| 09:00 | How Are We Doing? Results of the BTS Pilot Audit | Emma O’Dowd (ENG) |
| 09:20 | Quality Indicators and Standards for EBUS | Daniel Steinfort (AUS) |
| 09:40 | Where now? The Future of Interventional Bronchoscopy | Ricky Thakrar (ENG) |
| 10:00 | Panel Discussion |
| 12:00 – 13:30 | Session 10: UK Academic Trial Landscape |
LEVEL 3 SIDLAW/PENTLAND Chairs: Sanjay Popat (ENG) and Fiona Blackhall (ENG) |
| 12:00 | BTOG Research Group | Sanjay Popat (ENG) |
| 12:10 | EORTC Update | Mariana Brandao (BEL) |
| 12:20 | ETOP Update | Sanjay Popat (ENG) |
| 12:30 | CONCORDE | Alastair Greystoke (ENG) |
| 12:45 | TOURIST | Matthew Hatton (ENG) |
| 13:00 | REFINE | Michael Seckl (ENG) |
| 13:15 | THROMBO-STOP | Gary Middleton (ENG) |
| 12:00 – 13:30 | Session 10: BTOG/LCNUK Nurses Joint Session |
LEVEL 0 TINTO/MOORFOOT Chairs: Julia McAdam (ENG) and Paula Shepherd (ENG) |
| 12:00 | Introductions | |
| 12:05 | Thymoma Update | Chloe Holmes (ENG)/ Marrika Colvin (ENG) |
| 12:25 | Questions | |
| 12:35 | Lung iAct Study | Christopher Dodd (ENG) |
| 12:55 | Becoming an associate principal investigator – the experience of a lung cancer CNS as part of the Lung iAct study | Bing Smith (ENG) |
| 13:15 | Questions |
| 14:45 – 16:15 | Session 11: AI in Thoracic Oncology |
LEVEL 3 PENTLAND Chairs: Adam Januszewski (ENG) and John Edwards (ENG) |
| 14:45 | What Does It All Mean? What You Need To Know About AI | Anita Grigoriadis (ENG) |
| 15:00 | Enhancing Radiology Through AI | Rebecca Wray (ENG) |
| 15:15 | AI in Pathological Diagnosis of Lung Cancer | Mehrdad Rakaee (NOR) |
| 15:30 | AI Support in Clinical Decision Making | Arsela Prelaj (ITA) |
| 15:45 | Panel Discussion | |
| 16:00 | Close of the 24th Annual Conference |
BTOG 2026 Conference Dinner – Thursday – 19:30 – Carriages at 01:00
Pre-booked – ticketed dinner
Dress code: black tie or lounge suit and tie or cocktail wear (no jeans or casual dress please).
Make your own travel arrangements to the National Museum of Scotland, Chambers Street, Edinburgh, EH1 1JF to arrive from 19:30 for dinner at 20:00.
Except for a few reserved tables – please feel free to sit wherever you like.
|
Wednesday 13:00 – 13:45 |
LEVEL 3 FINTRY Satellite Symposium Sponsored by MSD Join MSD’s promotional symposium with Dr Toby Talbot, Dr Brian Clark and Rachel Powell discussing the impact of immunotherapy in metastatic NSCLC. The intended audience is UK HCPs only. This promotional symposium has been fully funded and organised by MSD. MSD products will be discussed. Prescribing information and adverse event reporting information will be available at the meeting.
|
|
Wednesday 15:30 – 16:15 |
LEVEL 0 TINTO/MOORFOOT Satellite Symposium Sponsored by MSD Join MSD’s promotional symposium with Dr Jason Adhikaree and Mr Timothy Batchelor discussing eligibility and delivery of perioperative and adjuvant immunotherapy in early-stage NSCLC. The intended audience is UK HCPs only. This promotional symposium has been fully funded and organised by MSD. MSD products will be discussed. Prescribing information and adverse event reporting information will be available at the meeting.
|
|
Wednesday 17:45 – 18:30 |
LEVEL 3 FINTRY Satellite Symposium Sponsored by Johnson & Johnson 1L cEGFR+ advanced NSCLC: Redefining the treatment landscape Chaired by Professor Samreen Ahmed, this symposium will explore the evolving 1L cEGFR+ advanced NSCLC landscape, highlighting key data and patient management considerations. This is a promotional symposium by J&J intended for UK healthcare professionals only. J&J products will be discussed and prescribing information will be available at the symposium. CP-563452 | February 2026
|
|
Wednesday 17:45 – 18:30 |
LEVEL 0 TINTO/MOORFOOT Satellite Symposium Sponsored by Bristol Myers Squibb Join Chair Prof Patrick Forde (IRE), Dr Annabel Sharkey (ENG), Dr Alexandros Georgiou (ENG) and Ms Hayley English (ENG) to discuss from evidence to action: Patient-centred treatment strategies for early-stage resectable NSCLC. BMS medicines will be discussed at this meeting. Intended for UK HCPs only.
|
|
Thursday 10:45 – 11:30 |
LEVEL 3 PENTLAND Satellite Symposium Sponsored by Pfizer ALK+ve aNSCLC: Current Conclusions from the Clatterbridge Collective Presented by Dr Carles Escriu, Dr Jonathan Heseltine & Sarah Rose, as they discuss their experience in a mutation-driven lung cancer clinic at The Clatterbridge Cancer Centre. This is a promotional symposium, intended audience is UK HCPs only. |
|
Thursday 10:45 – 11:30 |
LEVEL 0 TINTO/MOORFOOT Satellite Symposium Sponsored by Guardant Health FAST, SIMPLE, TRANSFORMATIVE LIQUID BIOPSY IN LUNG CANCER Diagnostic revolution or standard of care? Join an expert panel to discuss how liquid biopsy is becoming the new standard of care and what this means for your patients. Professor Sanjay Popat, The Royal Marsden NHS Foundation Trust, Fulham Road Dr Riyaz Shah, Kent Oncology Centre, Maidstone and Tunbridge Wells NHS Trust Josh Wharton; Lung Cancer CNS, Salford Care Organisation, Part of Northern Care Alliance, NHS Foundation Trust |
|
Thursday 13:15 – 14:00 |
LEVEL 0 TINTO/MOORFOOT Satellite Symposium Sponsored by AstraZeneca From data to impact: delivering patient‑first efficacy in EGFRm NSCLC This is a promotional meeting, prescribing information will be made available at the meeting. Join Prof. Pasi Jänne and Dr. Tanya Ahmad for a focused discussion on translating evidence into real‑world impact for patients with EGFR‑mutated NSCLC. Building on a legacy for patients, this session will distil the latest efficacy data and practical strategies with patient‑first principles — balancing survival with patient experience. JBN: GB-72114 Date of preparation: November 2025
|
|
Thursday 16:00 – 16:45 |
LEVEL 3 FINTRY From Biopsy to Breakthrough: Navigating Tissue Challenges and Emerging Genomic Solutions Professor Neal Navani, Professor of Respiratory Medicine, UCL, Dr David Dorward, Consultant Pathologist, Edinburgh and Dr Magda Meissner, Clinical Academic and Oncologist, Cardiff. This Boehringer Ingelheim-funded educational symposium brings together a respiratory physician, an oncologist, and a pathologist to discuss challenges in lung cancer care, including tissue biopsy adequacy, ctDNA’s evolving role, and the value of multidisciplinary collaboration. Boehringer Ingelheim provided logistical and financial support for the BTOG conference but apart from this symposium, had no further input into the conference agenda. NP-GB-106811 January 2026
|
|
Thursday 16:00 – 16:45 |
LEVEL 0 TINTO/MOORFOOT Satellite Symposium Sponsored by Roche Lung Cancer Expert Forum: Why IO Flexibility & Rapid Treatment Pathways Matter Speakers: Professor Alastair Greystoke (chair), Professor Raffaele Califano and Dr Joanne Evans This is a promotional symposium for UK HCPs only. Prescribing information will be available at the end of the symposium.
|
|
Friday 11:00 – 11:45 |
LEVEL 0 TINTO/MOORFOOT Satellite Symposium Sponsored by AstraZeneca Choosing the right IO: MDT Strategies to extend survival and improve quality of life This is a promotional meeting, prescribing information will be made available at the meeting. Join Dr. David Woolf, Dr. Sean Dulloo, Dr. Ananth Sivanandan and Dr. Leanne Ashrafian for a patient-centric discussion on MDT strategies to extend survival and improve quality of life in IO eligible patients. An interactive debate with Q&A throughout. JBN: GB-73507 Date of preparation: January 2026
|
|
Friday 13:45 – 14:30 |
LEVEL 3 FINTRY Satellite Symposium Sponsored by Takeda Join Dr Yvonne Summers, Emma Halkyard and Dr Sam Khan for a Takeda-sponsored promotional symposium focusing on the changing treatment landscape and optimisation of long-term management of patients with ALK+ aNSCLC. The experts will give their insights into personalised care which will be further explored using a patient case study. For a UK healthcare professional audience only. Takeda medicines will be discussed.
|
|
Friday 13:45 – 14:30 |
LEVEL 3 SIDLAW Satellite Symposium Sponsored by Merck Serono Ltd Join Prof. Martin Forster and an expert faculty to discuss the importance of identifying METex14 skipping alterations in patients with NSCLC, with a focus on practical considerations and future directions for optimising precision oncology in NSCLC. This symposium is intended for UK HCPs only. |
Watch our video recap of BTOG 2026 or visit the event archive to learn more about our Annual Conference
The presentations and videos from BTOG2026 are available now for members in the Members’ Area of the BTOG website.

